South San Francisco, CA 94083, US
Biotechnology
www.calithera.com
Calithera is a development stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer.
They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.
Dr. Molineaux is a co-founder of Calithera Biosciences and has served as the companys Chief Executive Officer since the companys founding in June 2010. Dr. Molineaux was most recently a founder, CSO and CEO of Proteolix, a company that discovered and developed proteasome inhibitors for the treatment of cancer and autoimmune disease. Prior to joining Proteolix, Dr. Molineaux was Vice President, Biology at Rigel Pharmaceuticals from 2000 to 2003. Before that, she was Vice President, Biology at Praelux, and from 1994 through 1999, Dr. Molineaux served as Vice President of Drug Development at Praecis Pharmaceuticals. From 1989 until 1994 she was a scientist in the Immunology group at Merck, in Rahway, NJ. Dr. Molineaux received a B.S. degree in Biology from Smith College, a Ph.D. degree in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University
Dr. Bennett has served as the Senior Vice President of Research at Calithera Biosciences since the companys founding in June 2010. Prior to joining Calithera, Dr. Bennett was at Proteolix in South San Francisco, CA from 2003 to 2009, serving as the Vice President of Research from 2006 to 2009 and as Director of Biological Research, from the companys founding in 2003 through 2005. Prior to joining Proteolix, Dr. Bennett was Director of Cell Biology at Rigel Pharmaceuticals in South San Francisco, CA from 1999 to 2003. From 1993 through 1999, Dr. Bennett was an Assistant Professor in the Department of Molecular and Cell Biology at the University of California, Berkeley. Dr. Bennett received a B.S. degree in Biochemistry and Biophysics from Oregon State University, a Ph.D. degree in Neuroscience from the California Institute of Technology, and completed postdoctoral fellowships at the European Molecular Biology Laboratory and Stanford University.
Jean M. George has served on our Board of Directors since 2005.
Ms. George is a General Partner at Advanced Technology Ventures.
Ms. George joined the firm in 2002 and serves as the firms East Coast lead partner for healthcare investments.
Ms. George brings more than 20 years of biopharmaceutical industry experience to the Board, including service at Genzyme Corporation from 1988 to 1998. At Genzyme, Ms. George held a variety of operational roles in marketing, product development, and business development, including Vice President of Global Sales and Marketing. She also worked as a Vice President and Founder of Genzymes Tissue Repair Division.
In 1998, Ms. George joined the venture capital community and was appointed to lead BancBoston Ventures life sciences investments.
Ms. George is currently a Director of Acceleron Pharmaceuticals, Calithera Biosciences, Hydra Biosciences, and Portola Pharmaceuticals.
Ms. George was a Director of Hypnion, Inc. and Proteolix, Inc.
Prior Year Revenue | Current Year Revenue | Next Year Revenue |
---|---|---|
Sign up as Investor | Sign up as Investor | Sign up as Investor |
Company Age | Employees | Sub-Industry |
---|---|---|
7 years, 1 month | 4 | Other Biotechnology |
Company Type | Stock Exchange | Stock Symbol |
---|---|---|
Privately-Held | – | – |